|
1
|
Patard JJ, Pignot G, Escudier B, Eisen T,
Bex A, Sternberg C, Rini B, Roigas J, Choueiri T, Bukowski R, et
al: ICUD-EAU International Consultation on Kidney Cancer 2010:
Treatment of metastatic disease. Eur Urol. 60:684–690. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Motzer RJ and Bukowski RM: Targeted
therapy for metastatic renal cell carcinoma. J Clin Oncol.
24:5601–5608. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Canil C, Hotte S, Mayhew LA, Waldron TS
and Winquist E: Interferon-alfa in the treatment of patients with
inoperable locally advanced or metastatic renal cell carcinoma: a
systematic review. Can Urol Assoc J. 4:201–208. 2010.PubMed/NCBI
|
|
4
|
Tanigawa G, Kawashima A, Yamaguchi S,
Nishimura K, Miyoshi S, Kajikawa J, Meguro N, Yosioka T, Oka T,
Hara T, et al Osaka Renal Cell Carcinoma Clinical Study
Collaboration: Clinical outcome and prognostic factors of sorafenib
in Japanese patients with advanced renal cell carcinoma in general
clinical practice. Jpn J Clin Oncol. 41:1265–1270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yuasa T, Tsuchiya N, Urakami S, Horikawa
Y, Narita S, Inoue T, Saito M, Yamamoto S, Yonese J, Fukui I, et
al: Clinical efficacy and prognostic factors for overall survival
in Japanese patients with metastatic renal cell cancer treated with
sunitinib. BJU Int. 109:1349–1354. 2012. View Article : Google Scholar
|
|
6
|
Naito S, Tsukamoto T, Murai M, Fukino K
and Akaza H: Overall survival and good tolerability of long-term
use of sorafenib after cytokine treatment: final results of a phase
II trial of sorafenib in Japanese patients with metastatic renal
cell carcinoma. BJU Int. 108:1813–1819. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Robert C, Thomas L, Bondarenko I, O’Day S,
Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al:
Ipilimumab plus dacarbazine for previously untreated metastatic
melanoma. N Engl J Med. 364:2517–2526. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hodi FS, O’Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Postow MA, Callahan MK and Wolchok JD: The
antitumor immunity of ipilimumab: (T-cell) memories to last a
lifetime? Clin Cancer Res. 18:1821–1823. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ascierto PA, Marincola FM and Ribas A:
Anti-CTLA4 monoclonal antibodies: the past and the future in
clinical application. J Transl Med. 9:1962011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Graziani G, Tentori L and Navarra P:
Ipilimumab: a novel immunostimulatory monoclonal antibody for the
treatment of cancer. Pharmacol Res. 65:9–22. 2012. View Article : Google Scholar
|
|
12
|
Hodi FS, Mihm MC, Soiffer RJ, Haluska FG,
Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A,
et al: Biologic activity of cytotoxic T lymphocyte-associated
antigen 4 antibody blockade in previously vaccinated metastatic
melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA.
100:4712–4717. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Small EJ, Tchekmedyian NS, Rini BI, Fong
L, Lowy I and Allison JP: A pilot trial of CTLA-4 blockade with
human anti-CTLA-4 in patients with hormone-refractory prostate
cancer. Clin Cancer Res. 13:1810–1815. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Blansfield JA, Beck KE, Tran K, Yang JC,
Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C,
et al: Cytotoxic T-lymphocyte-associated antigen-4 blockage can
induce autoimmune hypophysitis in patients with metastatic melanoma
and renal cancer. J Immunother. 28:593–598. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Youn JI and Gabrilovich DI: The biology of
myeloid-derived suppressor cells: the blessing and the curse of
morphological and functional heterogeneity. Eur J Immunol.
40:2969–2975. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ostrand-Rosenberg S: Myeloid-derived
suppressor cells: more mechanisms for inhibiting antitumor
immunity. Cancer Immunol Immunother. 59:1593–1600. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gabrilovich DI and Nagaraj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ostrand-Rosenberg S, Sinha P, Beury DW and
Clements VK: Cross-talk between myeloid-derived suppressor cells
(MDSC), macrophages, and dendritic cells enhances tumor-induced
immune suppression. Semin Cancer Biol. 22:275–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bierie B and Moses HL: Transforming growth
factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth
Factor Rev. 21:49–59. 2010. View Article : Google Scholar :
|
|
20
|
Porembka MR, Mitchem JB, Belt BA, Hsieh
CS, Lee HM, Herndon J, Gillanders WE, Linehan DC and Goedegebuure
P: Pancreatic adenocarcinoma induces bone marrow mobilization of
myeloid-derived suppressor cells which promote primary tumor
growth. Cancer Immunol Immunother. 61:1373–1385. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fujita M, Kohanbash G, Fellows-Mayle W,
Hamilton RL, Komohara Y, Decker SA, Ohlfest JR and Okada H: COX-2
blockade suppresses gliomagenesis by inhibiting myeloid-derived
suppressor cells. Cancer Res. 71:2664–2674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Srivastava MK, Zhu L, Harris-White M, Kar
UK, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett
S, et al: Myeloid suppressor cell depletion augments antitumor
activity in lung cancer. PLoS One. 7:e406772012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao M, Xu Y, Youn JI, Cabrera R, Zhang X,
Gabrilovich D, Nelson DR and Liu C: Kinase inhibitor sorafenib
modulates immunosuppressive cell populations in a murine liver
cancer model. Lab Invest. 91:598–608. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takeuchi A, Eto M, Tatsugami K, Yamada H,
Oki T, Kiyoshima K, Yoshikai Y and Naito S: Mechanism of
synergistic antitumor effect of sorafenib and interferon-α on
treatment of renal cell carcinoma. J Urol. 184:2549–2556. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Horlad H, Fujiwara Y, Takemura K, Ohnishi
K, Ikeda T, Tsukamoto H, Mizuta H, Nishimura Y, Takeya M and
Komohara Y: Corosolic acid impairs tumor development and lung
metastasis by inhibiting the immunosuppressive activity of
myeloid-derived suppressor cells. Mol Nutr Food Res. 57:1046–1054.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Figlin R, Sternberg C and Wood CG: Novel
agents and approaches for advanced renal cell carcinoma. J Urol.
188:707–715. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Patel PH, Chaganti RS and Motzer RJ:
Targeted therapy for metastatic renal cell carcinoma. Br J Cancer.
94:614–619. 2006.PubMed/NCBI
|
|
28
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
